ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Top 50 High-Quality Dividend Growth Stocks For December 2025 [Seeking Alpha]
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
Is It Too Late To Consider ResMed After Obesity and Sleep Apnea Headlines? [Yahoo! Finance]
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.